Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Non-Drug Studies

    New Non-Drug Study Opportunities Now Available Through Prism Research!

     

    Prism Research is proud to announce that we are now recruiting for non-drug studies!  You or someone you know might be qualified to participate in these studies.

     

    What are Non-Drug Studies?

    Medical devices like auto-injection pens, inhalers, and breast pumps must go through testing before they can be made available to the public.  In Non-Drug Studies, participants will simulate use of a medical device and provide feedback to how easy it was to use the device.  Just like drug-studies, participants receive financial compensation for their time

     

    Who can participate in Non-Drug Studies?

    Anyone who meets the qualifications for a specific study can participate and there will be many future opportunities.  Right now, we are specifically looking for the following people for multiple studies throughout the spring and summer:

     

    • People diagnosed with Rheumatoid Arthritis
    • Caregivers for people with Rheumatoid Arthritis

     

    Email a recuriter or call 651-289-2096 for more info!

  • Do You Have Rheumatoid Arthrist (RA)? Doyou You Take Care of Someone with RA?

    DO YOU HAVE RHEUMATOID ARTHRITIS (RA)?

    DO YOU TAKE CARE OF SOMEONE WITH RA?

    YOU MAY QUALIFY FOR A SIMULATED USE RESEARCH STUDY

     

    WHERE:  1000 Westgate Drive, St. Paul MN 55114

    COMPENSATION: Up to $300. Two study visits at $100 per hour.

    DETAILS:  This study is about using an auto-injector to give shots to people with rheumatoid arthritis, sometimes called RA.

    The study involves simulated use; you will only pretend to use the syringe.

    You will give a shot into a foam pad; not into yourself or another person.

    The auto-injector will be filled with water, not real medicine.

    You will be asked about your experience with RA and about your experience with the auto-injector.

    You will be video and/or audio recorded during your study visits. You may be photographed.

     

    HOW YOU QUALIFY:            People with RA:

    • Your doctor has told you that you have Rheumatoid Arthritis (RA).
    • Your RA must affect your hands, such as swelling, pain, change in size or shape or difficulty doing simple tasks.

     

                    People who take care of someone with RA (Caregiver):

    • You must assist a Rheumatoid Arthritis patient with daily tasks.

                                       

     

    for more information, Contact

    Molly; Prism Clinical Research

    Phone:  651-289-2096        Email:  mhair@prismresearchinc.com

  • Study 1608: Healthy Male and Female Particpants


    Research Purpose: Study 1608 is designed to evaluate an investigational drug being developed for the treatment of chronic inflammatory diseases. Participants will receive once daily oral dose amounts for 10 days of the investigational drug or placebo.  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug
    • The general safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women must be post-menopausal or surgically sterile and who are not breast feeding or lactating are allowed to participate. 

    Age

    18-55 years

    Body Mass Index (BMI)

    Between 18-30 kg/m²

    Tobacco/Nicotine Use

    No more than the equivalent of 5 cigarettes/week in the 2 months prior to screen.  Able and willing to abstain from all tobacco use for 7 days prior to screen until the end of the study

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year before the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks.

    Inpatient Stay

    • Participants will admit to Prism Clinical Research one time for 14 overnights

    Outpatient Visits

    • There is one outpatient visit

     

    Compensation for participation time: Up to $3,600

  • Study 1321: Healthy Participants

    Research Purpose:  Study 1321 is designed to evaluate an investigational drug being developed for the treatment of certain types of inflammatory disorders. The investigational drug will be given orally to healthy participants.  The purpose of the study is to determine how much of the investigational drug enters the blood stream when given at different dose levels; whether having an empty or full stomach affects how much of the investigational drug enters the blood stream; and how well the body tolerates the investigational drug.

    Screening Qualifications: Participants must meet the following minimum criteria in order to qualify for a screening appointment:

    • Age 18-55 years
    • Body Mass Index (BMI) between 18-32
    • Must be healthy; not being evaluated or treated for any medical conditions.
    • Cannot take medications on a regular basis (Exception: women can be using an prescribed hormonal birth control)
    • No history of cancer (Exception: cured basal or squamous cell skin cancers)
    • No history of drug addiction or alcoholism 12 months prior to the screening appointment
    • No use of more than the equivalent of 5 cigarettes per week in the two months before the screening appointment.
    • Must be able and willing to refrain from use of tobacco or nicotine containing products one week before the study starts until the end of the study
    • Must be able and willing to eat/drink a study specific meal which includes pork, eggs, dairy, and gluten.

    Study Time Commitment: For participants who qualify for the study based on screening results, study participation will last for approximately 3 ½ weeks.  During that time, participants will stay at Prism Clinical Research for three short inpatient stays lasting approximately 72 hours (three overnights) each time.  The inpatient stays will be separated by one week.  There will be one brief outpatient visit following the final inpatient stay. 

    Compensation: up to $2550 for participation time 

  • Study 1518: Healthy Male and Female Participants

    Research Purpose: Study 1518 is designed to evaluate an investigational drug being developed for the treatment of cancer. Participants will receive up to 3 intravenous (IV) doses of the investigational drug alone or along with companion medications.  The following will be evaluated:

    • How the body’s immune system responds to the investigational drug
    • How quickly the body process and eliminates the investigational drug
    • The general safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

     

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-65 years

    Tobacco/Nicotine Use

    No more than the equivalent of 10 cigarettes/week in the 3 months prior to screen.  Able and willing to abstain from all tobacco use  for 14 days prior to screen until  the end of the study

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year before the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

    Allowed Medications

    Prescribed/stable hormonal birth control is allowed

    Allergy History

    No past or current allergy to baker’s yeast

  • Research Study 1602: Healthy Male and Female Participants

    Research Purpose:  Study 1602 is designed to evaluate three different oral formulations of an investigational drug being developed for the treatment of human rhinovirus.  The following will be evaluated:

    • How each of the three formulations of the investigational drug impacts the body.
    • The safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Only Women who are not breastfeeding, pregnant, or planning to become pregnant are allowed to participate. 

    Age

    19-60 years

    Body Mass Index (BMI)

    18 to 32

    Weight

    Must weigh greater or equal to 110 pounds

    Tobacco/Nicotine Use

    Must be able and willing to abstain from tobacco/nicotine and electronic cigarettes 14 days before the start of the study until the final study visit. 

    Drug Testing

    Must test negative for drugs of abuse. 

    Substance Abuse History

    No history of drug or alcohol abuse within 2 years before the start of the study

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    • No chronic use of any prescription medications in the 90 days prior to the start of the study through the final study visit
    • No over-the-counter medications, supplements, or vitamins 7 days prior to the start of the stud through the final study visit.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 3 and a half weeks. 

    In-house Stays

    Participants will stay at Prism Clinical Research three times. 

    • Each in-house stays will last approximately 60 hours (2 overnights)
    • The in-house stays will be separated by approximately one week

    Study Visits

    The third in-house stay is followed by one brief study visit.

     

    Compensation: Up to $1,885.00 for study participation time.

     

     

     

     
       

     


    For information regarding this study contact Sarah: 651-368-3360 or sarahl@prismresearchinc.com

Current Studies

Contact a Recruiter

  • Kevin Fitzgerald
    651-289-2098 Email Me

    Recruiter extaordinaire.

  • Molly Hair
    651-289-2096 Email Me
  • Andy Halverson
    651-724-8399 Email Me
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Non-Drug Studies

    New Non-Drug Study Opportunities Now Available Through Prism Research!

     

    Prism Research is proud to announce that we are now recruiting for non-drug studies!  You or someone you know might be qualified to participate in these studies.

     

    What are Non-Drug Studies?

    Medical devices like auto-injection pens, inhalers, and breast pumps must go through testing before they can be made available to the public.  In Non-Drug Studies, participants will simulate use of a medical device and provide feedback to how easy it was to use the device.  Just like drug-studies, participants receive financial compensation for their time

     

    Who can participate in Non-Drug Studies?

    Anyone who meets the qualifications for a specific study can participate and there will be many future opportunities.  Right now, we are specifically looking for the following people for multiple studies throughout the spring and summer:

     

    • People diagnosed with Rheumatoid Arthritis
    • Caregivers for people with Rheumatoid Arthritis

     

    Email a recuriter or call 651-289-2096 for more info!

  • Do You Have Rheumatoid Arthrist (RA)? Doyou You Take Care of Someone with RA?

    DO YOU HAVE RHEUMATOID ARTHRITIS (RA)?

    DO YOU TAKE CARE OF SOMEONE WITH RA?

    YOU MAY QUALIFY FOR A SIMULATED USE RESEARCH STUDY

     

    WHERE:  1000 Westgate Drive, St. Paul MN 55114

    COMPENSATION: Up to $300. Two study visits at $100 per hour.

    DETAILS:  This study is about using an auto-injector to give shots to people with rheumatoid arthritis, sometimes called RA.

    The study involves simulated use; you will only pretend to use the syringe.

    You will give a shot into a foam pad; not into yourself or another person.

    The auto-injector will be filled with water, not real medicine.

    You will be asked about your experience with RA and about your experience with the auto-injector.

    You will be video and/or audio recorded during your study visits. You may be photographed.

     

    HOW YOU QUALIFY:            People with RA:

    • Your doctor has told you that you have Rheumatoid Arthritis (RA).
    • Your RA must affect your hands, such as swelling, pain, change in size or shape or difficulty doing simple tasks.

     

                    People who take care of someone with RA (Caregiver):

    • You must assist a Rheumatoid Arthritis patient with daily tasks.

                                       

     

    for more information, Contact

    Molly; Prism Clinical Research

    Phone:  651-289-2096        Email:  mhair@prismresearchinc.com

  • Study 1608: Healthy Male and Female Particpants


    Research Purpose: Study 1608 is designed to evaluate an investigational drug being developed for the treatment of chronic inflammatory diseases. Participants will receive once daily oral dose amounts for 10 days of the investigational drug or placebo.  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug
    • The general safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women must be post-menopausal or surgically sterile and who are not breast feeding or lactating are allowed to participate. 

    Age

    18-55 years

    Body Mass Index (BMI)

    Between 18-30 kg/m²

    Tobacco/Nicotine Use

    No more than the equivalent of 5 cigarettes/week in the 2 months prior to screen.  Able and willing to abstain from all tobacco use for 7 days prior to screen until the end of the study

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year before the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks.

    Inpatient Stay

    • Participants will admit to Prism Clinical Research one time for 14 overnights

    Outpatient Visits

    • There is one outpatient visit

     

    Compensation for participation time: Up to $3,600

  • Study 1321: Healthy Participants

    Research Purpose:  Study 1321 is designed to evaluate an investigational drug being developed for the treatment of certain types of inflammatory disorders. The investigational drug will be given orally to healthy participants.  The purpose of the study is to determine how much of the investigational drug enters the blood stream when given at different dose levels; whether having an empty or full stomach affects how much of the investigational drug enters the blood stream; and how well the body tolerates the investigational drug.

    Screening Qualifications: Participants must meet the following minimum criteria in order to qualify for a screening appointment:

    • Age 18-55 years
    • Body Mass Index (BMI) between 18-32
    • Must be healthy; not being evaluated or treated for any medical conditions.
    • Cannot take medications on a regular basis (Exception: women can be using an prescribed hormonal birth control)
    • No history of cancer (Exception: cured basal or squamous cell skin cancers)
    • No history of drug addiction or alcoholism 12 months prior to the screening appointment
    • No use of more than the equivalent of 5 cigarettes per week in the two months before the screening appointment.
    • Must be able and willing to refrain from use of tobacco or nicotine containing products one week before the study starts until the end of the study
    • Must be able and willing to eat/drink a study specific meal which includes pork, eggs, dairy, and gluten.

    Study Time Commitment: For participants who qualify for the study based on screening results, study participation will last for approximately 3 ½ weeks.  During that time, participants will stay at Prism Clinical Research for three short inpatient stays lasting approximately 72 hours (three overnights) each time.  The inpatient stays will be separated by one week.  There will be one brief outpatient visit following the final inpatient stay. 

    Compensation: up to $2550 for participation time 

  • Study 1518: Healthy Male and Female Participants

    Research Purpose: Study 1518 is designed to evaluate an investigational drug being developed for the treatment of cancer. Participants will receive up to 3 intravenous (IV) doses of the investigational drug alone or along with companion medications.  The following will be evaluated:

    • How the body’s immune system responds to the investigational drug
    • How quickly the body process and eliminates the investigational drug
    • The general safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

     

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-65 years

    Tobacco/Nicotine Use

    No more than the equivalent of 10 cigarettes/week in the 3 months prior to screen.  Able and willing to abstain from all tobacco use  for 14 days prior to screen until  the end of the study

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year before the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

    Allowed Medications

    Prescribed/stable hormonal birth control is allowed

    Allergy History

    No past or current allergy to baker’s yeast

  • Research Study 1602: Healthy Male and Female Participants

    Research Purpose:  Study 1602 is designed to evaluate three different oral formulations of an investigational drug being developed for the treatment of human rhinovirus.  The following will be evaluated:

    • How each of the three formulations of the investigational drug impacts the body.
    • The safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Only Women who are not breastfeeding, pregnant, or planning to become pregnant are allowed to participate. 

    Age

    19-60 years

    Body Mass Index (BMI)

    18 to 32

    Weight

    Must weigh greater or equal to 110 pounds

    Tobacco/Nicotine Use

    Must be able and willing to abstain from tobacco/nicotine and electronic cigarettes 14 days before the start of the study until the final study visit. 

    Drug Testing

    Must test negative for drugs of abuse. 

    Substance Abuse History

    No history of drug or alcohol abuse within 2 years before the start of the study

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    • No chronic use of any prescription medications in the 90 days prior to the start of the study through the final study visit
    • No over-the-counter medications, supplements, or vitamins 7 days prior to the start of the stud through the final study visit.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 3 and a half weeks. 

    In-house Stays

    Participants will stay at Prism Clinical Research three times. 

    • Each in-house stays will last approximately 60 hours (2 overnights)
    • The in-house stays will be separated by approximately one week

    Study Visits

    The third in-house stay is followed by one brief study visit.

     

    Compensation: Up to $1,885.00 for study participation time.

     

     

     

     
       

     


    For information regarding this study contact Sarah: 651-368-3360 or sarahl@prismresearchinc.com

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel